Stay updated with breaking news from Nasdaq Mdgl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The […]
JMP Securities reissued their market outperform rating on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) in a report published on Friday, Benzinga reports. They currently have a $347.00 price objective on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on MDGL. StockNews.com upgraded Madrigal Pharmaceuticals to a sell rating […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) – Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Madrigal Pharmaceuticals in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the biopharmaceutical company will post earnings per share of ($5.11) for the […]
Bank of New York Mellon Corp boosted its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 4.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,786 shares of the biopharmaceutical company’s stock after acquiring […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and DMK Pharmaceuticals (NASDAQ:DMK – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership. Insider & Institutional Ownership 79.9% of Madrigal Pharmaceuticals […]